ライフサイエンスコーパス: paricalcitol

1 accompanied these renoprotective effects of paricalcitol.

2 roxylase, resulting in increased activity of paricalcitol.

3 secondary hyperparathyroidism received oral paricalcitol 1 mug/d for 3 months, and 8 patients matche

4 conclusion, 52 weeks of treatment with oral paricalcitol (1 mug one time daily) significantly improv

5 ere randomly assigned to receive either oral paricalcitol (1 mug) one time daily (n=30) or matching p

6 ompared the effect of 6-month treatment with paricalcitol (1 mug/d for 3 months and then uptitrated t

7 atment of the diabetic mice with losartan or paricalcitol (19-nor-1,25-dihydroxyvitamin D(2), an acti

8 This study investigated the effects of paricalcitol (19-nor-1,25-hydroxy-vitamin D(2)), a synth

9 Paricalcitol (19-nor-1alpha-25-dihydroxyvitamin D2), a n

10 ril (30 mg/L in drinking water; E), uremic + paricalcitol (19-nor; 0.8 microg/kg, three times a week)

11 cipients were randomized 1:1 to receive oral paricalcitol, 2 mug per day, for the first year posttran

12 pants were randomly assigned to receive oral paricalcitol, 2 mug/d (n =115), or matching placebo (n =

13 Of 40 patients receiving paricalcitol, 27 (68%) had at least a 30% decrease in se

14 alysis who started to receive treatment with paricalcitol (29,021 patients) or calcitriol (38,378 pat

15 Paricalcitol, a new vitamin D analogue, appears to lesse

16 Paricalcitol, a selective vitamin D receptor activator,

17 In vitro, paricalcitol abolished TGF-beta1-mediated E-cadherin sup

18 omatin immunoprecipitation assay showed that paricalcitol abolished the binding of p65 to its cognate

19 Paricalcitol administration resulted in a median percent

20 Paricalcitol administration to renal transplant patients

21 S induction depended on NF-kappaB signaling, paricalcitol affected neither TNF-alpha-mediated IkappaB

22 It is interesting that paricalcitol almost completely suppressed renal inductio

23 Administration of paricalcitol also ameliorated established proteinuria.

24 Paricalcitol also inhibited expression of proinflammator

25 ARalpha in PR9 cells, and the combination of paricalcitol and As2O3 enhanced their monocytic differen

26 In summary, the combination of paricalcitol and As2O3 potently decreased growth and ind

27 ant difference in adverse events between the paricalcitol and placebo-treated groups.

28 ns retrieved, six studies (four studies with paricalcitol and two studies with calcitriol) providing

29 -ray absorption, significantly improved with paricalcitol at 6 months (P<0.05 for both densities).

30 obably by increasing intracellular levels of paricalcitol by decreasing the function of the mitochond

31 owever, combined treatment with losartan and paricalcitol completely prevented albuminuria, restored

32 sues, we tested whether the vitamin D analog paricalcitol could ameliorate podocyte injury, proteinur

33 Paricalcitol decreases intact parathyroid hormone and th

34 Forty-eight week therapy with paricalcitol did not alter left ventricular mass index o

35 In vivo, paricalcitol did not block NF-kappaB nuclear translocati

36 hree times a week), and uremic + enalapril + paricalcitol (E + 19-nor).

37 In this study, we explored if paricalcitol enhanced anticancer effects of other clinic

38 roteinuric rats were treated with vehicle or paricalcitol for 6 consecutive weeks.

39 oid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7)

40 s of hypercalcemia were more frequent in the paricalcitol group compared with the placebo group.

41 olic lateral mitral annular tissue velocity (paricalcitol group, -0.01 cm/s [95% CI, -0.63 to 0.60 cm

42 dex did not differ between treatment groups (paricalcitol group, 0.34 g/m(2.7) [95% CI, -0.14 to 0.83

43 y 6.7 and 11.9 percent, respectively, in the paricalcitol group, as compared with 8.2 and 13.9 percen

44 emic vitamin D analogue (19-nor-1,25(OH)2D2; paricalcitol) had anticancer activity.

45 In vitro, paricalcitol induced a physical interaction between the

46 Paricalcitol induced monocytic differentiation of U937 A

47 ng-term studies are needed to assess whether paricalcitol-induced increase in KLOTHO gene expression

48 ic blockade of Wnt/beta-catenin signaling by paricalcitol inhibited MMP-7 expression in diseased kidn

49 a human proximal tubular cell line (HKC-8), paricalcitol inhibited RANTES mRNA and protein expressio

50 Furthermore, paricalcitol inhibited the TGF-beta1-mediated Snail indu

51 These results suggest that paricalcitol inhibits renal inflammatory infiltration an

52 A total of 78 patients (40 Paricalcitol injection, 38 placebo) achieved treatment p

53 These studies suggest that paricalcitol is able to ameliorate renal interstitial fi

54 Oral paricalcitol is effective in decreasing posttransplant h

55 epithelial cells, accompanied renal injury; paricalcitol largely abolished this induction of renal b

56 Paricalcitol largely preserved E-cadherin and reduced al

57 linically relevant dosages of calcitriol and paricalcitol may protect against CKD-stimulated vascular

58 effects of the VDR activators calcitriol and paricalcitol on aortic calcification in a mouse model of

59 -concept study aimed to assess the effect of paricalcitol on fibroblast growth factor-23/KLOTHO axis

60 We examined the effect of oral paricalcitol on posttransplant secondary hyperparathyroi

61 e effect of the synthetic vitamin D analogue paricalcitol on renal inflammation was investigated in a

62 After a 4-wk washout, paricalcitol or placebo was administered intravenously t

63 24-hour proteinuria level decreased only on paricalcitol (P<0.05).

64 effects of the vitamin D receptor activator paricalcitol (PARI) and dietary sodium restriction on re

65 Here, we investigated whether paricalcitol (PC, 19-nor-1,25(OH)(2)D(2)), an activated

66 Compared with vehicle-treated controls, paricalcitol preserved expression of nephrin, podocin, a

67 In summary, these findings suggest that paricalcitol prevents podocyte dysfunction, proteinuria,

68 O3 increased the transcriptional activity of paricalcitol probably by increasing intracellular levels

69 Paricalcitol reduced infiltration of T cells and macroph

70 Treatment with paricalcitol reduced parathyroid hormone levels within 4

71 These studies demonstrate that paricalcitol safely and effectively suppresses iPTH leve

72 pared with vehicle-treated proteinuric rats, paricalcitol showed markedly reduced renal lymphangiogen

73 Compared with vehicle controls, paricalcitol significantly attenuated renal interstitial

74 adynamic bone disorder; both calcitriol and paricalcitol stimulated osteoblast surfaces and rates of

75 Overall, 6-month paricalcitol supplementation reduced parathyroid hormone

76 In addition, paricalcitol suppressed renal TGF-beta1 and its type I r

77 The dose of paricalcitol that decreased iPTH by at least 30% became

78 atients who received 12 wk of treatment with paricalcitol, the levels of iPTH decreased significantly

79 d assessed changes after cholecalciferol and paricalcitol therapies in both vitamin D-responsive prot

80 ine phosphatase and osteocalcin decreased on paricalcitol therapy only and significantly differed bet

81 Two subjects required decreasing the dose of paricalcitol to 1 mug daily.

82 ith 64 percent among those who switched from paricalcitol to calcitriol (P=0.04).

83 Intact parathyroid hormone decreased in paricalcitol-treated patients (P < 0.0001).

84 lood mononuclear cells increased by 45.7% in paricalcitol-treated patients (P < 0.01), without change

85 Paricalcitol-treated patients showed a decrease in the m

86 confidence interval, 10 to 21 percent) among paricalcitol-treated patients than among calcitriol-trea

87 eving target serum iPTH levels in any of the paricalcitol-treated patients.

88 nge in controls, but it increased by 177% in paricalcitol-treated subjects (P < 0.0001).

89 One-year posttransplant, 29% of paricalcitol-treated subjects had hyperparathyroidism co

90 Paricalcitol treatment resulted in a significant reducti

91 However, paricalcitol treatment significantly reduced intact para

92 p65 formed a complex in tubular cells after paricalcitol treatment, which inhibited the ability of p

93 le range], -2.59 [-6.13 to 0.32] g/m(2) with paricalcitol versus -4.85 [-9.89 to 1.10] g/m(2) with pl

94 The mortality rate among patients receiving paricalcitol was 3417 per 19,031 person-years (0.180 per

95 ong patients who switched from calcitriol to paricalcitol was 73 percent, as compared with 64 percent

96 Paricalcitol was discontinued in four patients due to hy

97 Paricalcitol was well tolerated.

98 econdary hyperparathyroidism, calcitriol and paricalcitol were protective against aortic calcificatio

99 Paricalcitol, when combined with As2O3, showed a markedl

100 Patients who receive paricalcitol while undergoing long-term hemodialysis app